# Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

> **NCT05226390** · PHASE1 · TERMINATED · sponsor: **Hannover Medical School** · enrollment: 23 (actual)

## Conditions studied

- COVID-19 Vaccines

## Interventions

- **BIOLOGICAL:** MVA-SARS-2-ST

## Key facts

- **NCT ID:** NCT05226390
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-24
- **Primary completion:** 2023-11-21
- **Final completion:** 2023-11-21
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** cohort could not be recruited
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226390, "Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05226390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*